Glenn Miller, Ph.D., Joins MolecularMD as Chief Technology Officer and Executive Vice President

PORTLAND, OR--(Marketwired - Aug 8, 2013) - MolecularMD Corporation today announced that Dr. Glenn Miller has been appointed to the executive management team as Chief Technology Officer and Executive Vice President. Dr. Miller will play a principal role in expanding MolecularMD's leadership in developing and delivering complete molecular diagnostic solutions that accelerate the development and commercialization of targeted cancer therapies. 

Dr. Miller is an accomplished leader with expertise in drug and clinical development, biomarkers and diagnostics, personalized medicine and business development. Dr. Miller was most recently Vice President and Head of Personalized Healthcare & Biomarker Strategy for AstraZeneca and previously held a variety of roles at Genzyme culminating in his role as Vice President and General Manager of Genzyme Analytical Services, a division of Genzyme Genetics that was acquired by LabCorp in 2010. He sits on the Board of Directors of BioMarker Strategies, has served as Chair of the Personalized Medicine Task Force of the European Biopharmaceutical Enterprises, a specialized group of the European Federation of Pharmaceutical Industry Associations and a member of the Clinical Sciences Committee of the Personalized Medicine Coalition. Dr. Miller has been a member of MolecularMD's Scientific Advisory Board since September 2012.

Sherry Snyder, CEO and Chairman at MolecularMD commented, "Glenn's leadership and industry acumen, coupled with his wealth of experience in the areas of clinical development and molecular diagnostics, make him well-suited to lead our technology and business growth in the coming years. We are pleased to welcome Glenn to the team."

Dr. Miller added, "With a history of innovation, clinical testing leadership and pharmaceutical industry collaboration, MolecularMD has repeatedly demonstrated the value of clinical laboratory testing and companion diagnostics to precision medicine. I am proud and excited to be joining this vibrant and growing company. I look forward to working with their strong and dedicated team of professionals as we deliver ever greater value to the biopharmaceutical industry and to the patients we all serve."

About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD incorporates gold-standard and innovative technologies in providing its partners with the highest quality results. Tests are designed to meet clinical trial needs, and MolecularMD has appropriate systems and standards in place to enable development of companion diagnostic tests in conjunction with partners' novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Dr. Brian Druker, director of the Knight Cancer Institute at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation.